PHASE III RANDOMIZED STUDY OF ENZASTAURIN/R‐CHOP VS PLACEBO/R‐CHOP IN FRONTLINE HIGH RISK DIFFUSE LARGE B CELL LYMPHOMA PATIENTS WITH GENOMIC BIOMARKER DGM1 (ENGINE STUDY)
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.37_2629
Abstract: Karyopharm Therapeutics, Kite Pharma, Lundbeck, Merck, Roche/Genentech, Inc., Seattle Genetics, Takeda, Teva, TG Therapeutics; Research Funding: Roche/Genentech, Inc. Sharman, J: Consultant Advisory Role: Pharmacyclics, Celgene, TG Therapeutics, Genentech, Inc., AbbVie, Acerta Pharma/AstraZeneca; Research Funding: Pharmacyclics,… read more here.
Keywords: gilead sciences; study; genentech inc; oncology ... See more keywords
995. Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline
Sign Up to like & getrecommendations! Published in 2020 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofaa439.1181
Abstract: DISCOVER is an ongoing trial comparing emtricitabine plus tenofovir alafenamide (F/TAF) or tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP). DISCOVER included some participants already taking F/TDF for PrEP at baseline (BL) creating a… read more here.
Keywords: gilead sciences; sciences inc; research; prep ... See more keywords
103. Persistence on F/TDF for HIV Pre-exposure Prophylaxis: Insights from Real-world Evidence
Sign Up to like & getrecommendations! Published in 2020 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofaa439.413
Abstract: Background: Daily F/TDF is highly effective for HIV pre-exposure prophylaxis (PrEP). Prior studies have found that women and people of younger age have lower adherence and lower persistence on PrEP, yet real-world evidence describing persistence… read more here.
Keywords: gilead sciences; sciences inc; prep; non persistence ... See more keywords
92. Obeldesivir Reduced SARS-CoV-2 Infectious Titers in the BIRCH Phase 3 Clinical Trial
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.029
Abstract: Abstract Background COVID-19 remains a serious condition, especially for those with certain risk factors. Obeldesivir (ODV) is an oral, broad spectrum, nucleoside analog prodrug inhibitor of SARS-CoV-2 RNA-dependent RNA polymerase. Methods BIRCH was a Phase… read more here.
Keywords: inc employee; sciences inc; gilead sciences; employee gilead ... See more keywords
P-1938. Impact of Race and Ethnicity on Patient-reported Health and Symptoms Following COVID-19 or Long COVID Diagnosis
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.2097
Abstract: Abstract Background SARS-CoV-2 infection and COVID-19 hospitalization and mortality rates are higher in Black and Hispanic patients compared to White patients. Patient perspectives give key insights into healthcare inequities and treatment disparities. This study aimed… read more here.
Keywords: covid; sciences inc; gilead sciences; black hispanic ... See more keywords
P-2021. How Have COVID-19 Treatment Guidelines and the Scientific Evidence Evolved throughout the Pandemic and Endemic Eras?
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.2178
Abstract: Abstract Background With progressive understanding of the natural history of COVID-19 and accumulation of knowledge on clinical management, treatment guidelines recommended several options including remdesivir (RDV), a broad-spectrum antiviral. Given the evolving nature of COVID-19,… read more here.
Keywords: gilead sciences; evidence; advisor consultant; consultant ... See more keywords
P-2025. Resistance Analyses from the Remdesivir Phase 2/3 CARAVAN Study in Pediatric and Neonatal Participants Hospitalized with COVID-19
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.2181
Abstract: Abstract Background Remdesivir (RDV) is a nucleotide analog prodrug approved for treatment of COVID-19. Here we present comprehensive SARS-CoV-2 resistance analyses from all cohorts of the Phase 2/3 CARAVAN study, which demonstrated the safety of… read more here.
Keywords: inc employee; sciences inc; gilead sciences; employee gilead ... See more keywords
P-474. Effects of Antiretroviral Resistance on Outcomes and Healthcare Resource Use of People with HIV in the United States and Europe – A Real-World Survey
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.673
Abstract: Abstract Background Resistance to key classes of ART leads to decreased treatment efficacy, virologic failure, and poorer clinical outcomes. Adding to current literature, this study reports current real-world trends between ART resistance mutations, healthcare resource… read more here.
Keywords: sciences inc; real world; adelphi real; gilead sciences ... See more keywords
P-550. Efficacy and Safety of B/F/TAF in Black Adults with HIV Who Are Treatment Naïve: 5-Year Follow-Up from Two Phase 3 Studies
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.749
Abstract: Abstract Background Black communities are disproportionately affected by HIV and may have a greater lifetime risk of comorbidities compared with non-Black people with HIV (PWH). Despite this, they have historically been underrepresented in clinical studies.… read more here.
Keywords: gilead sciences; black pwh; support; sciences inc ... See more keywords
P-581. Racial/Ethnic Disparities of Renal Outcomes in People with HIV (PWH) on Tenofovir Alafenamide (TAF) Based Antiretroviral Treatment (ART) Regimens in the Real World
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.779
Abstract: Abstract Background The risk of chronic kidney disease (CKD) is higher in PWH than HIV-negative persons. Black communities are not only disproportionately affected by HIV but also more at risk for kidney disease than other… read more here.
Keywords: gilead sciences; taf; black pwh; sciences inc ... See more keywords
P210 Efficacy and safety of filgotinib for patients with RA with inadequate response to methotrexate: FINCH1 primary outcome results
Sign Up to like & getrecommendations! Published in 2020 at "Rheumatology"
DOI: 10.1093/rheumatology/keaa111.205
Abstract: Filgotinib (FIL) is an oral, potent, selective Janus kinase 1 inhibitor that has shown good efficacy and was well tolerated for treatment of rheumatoid arthritis (RA). The objective of this study was to evaluate efficacy… read more here.
Keywords: gilead sciences; shareholder; sciences inc; gilead ... See more keywords